Marksans Pharma Ratios

Marksans Pharma Ltd Ratios

The Marksans Pharma Ltd Ratios page provides a complete fundamental analysis of Marksans Pharma Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Marksans Pharma Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Marksans Pharma Ltd (NSE: MARKSANS, BSE: 524404) is currently trading at ₹172.95, with a market capitalization of ₹78.85B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Marksans Pharma Ltd remains a key stock for fundamental analysis using Marksans Pharma Ltd Ratios.

Marksans Pharma Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Marksans Pharma Ltd P/E ratio currently stands at 26.48, making it one of the most tracked metrics in Marksans Pharma Ltd Ratios.

Historically, the Marksans Pharma Ltd P/E ratio has shown strong fluctuations:

• 2024: 26.48
• 2023: 21.89
• 2022: 11
• 2021: 10.10
• 2020: 8.67

The rising Marksans Pharma Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Marksans Pharma Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 4.08.

Historical P/B trend:

• 2024: 4.08
• 2023: 3.33
• 2022: 1.83
• 2021: 1.55

Marksans Pharma Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Marksans Pharma Ltd P/S ratio currently stands at 3.85, an important part of Marksans Pharma Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 3.85
• 2023: 3.16
• 2022: 1.58
• 2021: 1.26

The rising Marksans Pharma Ltd P/S ratio indicates improved revenue valuation by investors.

Marksans Pharma Ltd Price to Cash Flow Ratio (P/CF)

The Marksans Pharma Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 42.32.

Historical Marksans Pharma Ltd Price to Cash Flow Ratio:

• 2024: 42.32
• 2023: 26.82
• 2022: 12.11
• 2021: 19.44
• 2020: 11.91

The rising Marksans Pharma Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Marksans Pharma Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Marksans Pharma Ltd EV currently stands at ₹97.15B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 97.15B
• 2023: 64.32B
• 2022: 23.56B
• 2021: 16.46B

Marksans Pharma Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Marksans Pharma Ltd EV/EBITDA ratio is currently 18.33, a key metric in Marksans Pharma Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 18.33
• 2023: 13.97
• 2022: 6.70
• 2021: 6.56

Higher Marksans Pharma Ltd EV/EBITDA suggests premium valuation.

Marksans Pharma Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Marksans Pharma Ltd D/E ratio is currently 0.13, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.13
• 2023: 0.12
• 2022: 0.07
• 2021: 0.09

Marksans Pharma Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Marksans Pharma Ltd ROE currently stands at 16.80%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 16.80
• 2023: 16.47
• 2022: 18.07
• 2021: 17.67

Marksans Pharma Ltd maintains stable profitability levels.

Marksans Pharma Ltd Ratios Analysis Summary

The Marksans Pharma Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Marksans Pharma Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Marksans Pharma Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.